Podcasts about dbv technologies

Dans ce numéro du Journal des biotechs, Frédéric Gomez analyse les conséquences de la démission de Peter Marks de la FDA sur les biotechs et notamment Moderna. Il revient aussi sur la baisse du cours de Novo Nordisk et commente la récente levée de fonds de DBV Technologies.L'entretien est consacré à Hervé Affagard, directeur général de Maat Pharma. Il détaille notamment les résultats de phase III ARES pour MaaT013 dans le traitement de la maladie aiguë du greffon contre l'hôte et fait le point sur la stratégie de la biotech.Attention, investir en Bourse présente un risque de perte en capital, et le secteur des biotechs cotées amplifie ce risque. La probabilité de succès de ces sociétés est incertaine, et leur besoin de financement est régulier. En cas d'échec, la continuité de leur activité peut être menacée. Ce type d'investissement est réservé exclusivement aux particuliers avertis pleinement conscients de ces enjeux et prêts à accepter ces risques. Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Learn about ground-breaking news and updates from the recent American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting held this February in Washington, D.C. In lay relatable terms, FAACT's Medical Advisory Board Chair, Dr. Shahzad Mustafa, discusses the approval of Xolair and what it means for the food allergy community. He also shares his thoughts regarding treatments that are on-the-horizon for anaphylaxis from ARS Pharma, Bryn Pharma, Aquestive, DBV Technologies, and Blueprint Medicines. Resources to keep you in the know:New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies (Genentech)ARS PharmaBryn PharmaAquestiveDBV TechnologiesBlueprint MedicinesTakeda (EOHILIA)FAACT's Resources:Education Resource CenterDining Out & HandoutTraveling & Traveler's ChecklistBehavioral Health Resource CenterYou can find FAACT's Roundtable Podcast on Apple Podcast, Pandora, Spotify, Google Podcast, iHeart Radio or wherever you listen to your podcasts.Follow us on Facebook, Twitter, Instagram, Threads, LinkedIn, Pinterest, TikTok, and YouTube.Sponsored by: National Peanut BoardThanks for listening! FAACT invites you to discover more exciting food allergy resources at FoodAllergyAwareness.org!

Listen to Len Bacharier, MD and Sharon Dell, MD, FRCPC, as they highlight the natural course of pediatric asthma progression over time, discuss differences between spontaneous remission and on-treatment clinical remission, and provide a commentary on what we have learned from the recent developments around remission in adults and how it could relate more specifically to pediatric populations.   ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Len Bacharier, MD has served as an advisor, consultant, speaker, and/or investigator for AstraZeneca, Avillion, DBV Technologies, Genentech/Novartis, GlaxoSmithKline, Kinaset, OM Pharma, Recludix, Regeneron Pharmaceuticals, Inc., Sanofi, Vertex; has provided grant and/or research support for NIH (NHLBI, NIAID), Regeneron Pharmaceuticals, Inc., Sanofi; and has provided other support for DBV Technologies Sharon Dell, MD has served as an advisor, consultant, and/or speaker for  AstraZeneca, Novartis, Regeneron Pharmaceuticals, Sanofi; and has provided grant and/or research support for Boehringer Ingelheim, Merck, Parion Sciences, Sanofi, Vertex Pharmaceuticals © 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2305935 v1.0 12/2023 MAT-US-2305475 v1.0 - P Expiration Date: 12/22/2025

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/RGF865. CME/MOC/AAPA credit will be available until December 27, 2024.Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerPD Dr. med. Luc Biedermann has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; EsoCap AG; Janssen-Cilag AG; Lilly; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Speaker for AbbVie Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Co-Chair/PlannerJonathan Spergel, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ARS Pharmaceutical; DBV Technologies; Kaleo, Inc.; ReadySetFood; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/RGF865. CME/MOC/AAPA credit will be available until December 27, 2024.Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerPD Dr. med. Luc Biedermann has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; EsoCap AG; Janssen-Cilag AG; Lilly; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Speaker for AbbVie Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Co-Chair/PlannerJonathan Spergel, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ARS Pharmaceutical; DBV Technologies; Kaleo, Inc.; ReadySetFood; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/RGF865. CME/MOC/AAPA credit will be available until December 27, 2024.Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerPD Dr. med. Luc Biedermann has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; EsoCap AG; Janssen-Cilag AG; Lilly; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Speaker for AbbVie Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Co-Chair/PlannerJonathan Spergel, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ARS Pharmaceutical; DBV Technologies; Kaleo, Inc.; ReadySetFood; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/RGF865. CME/MOC/AAPA credit will be available until December 27, 2024.Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerPD Dr. med. Luc Biedermann has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; EsoCap AG; Janssen-Cilag AG; Lilly; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Speaker for AbbVie Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Co-Chair/PlannerJonathan Spergel, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ARS Pharmaceutical; DBV Technologies; Kaleo, Inc.; ReadySetFood; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/RGF865. CME/MOC/AAPA credit will be available until December 27, 2024.Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerPD Dr. med. Luc Biedermann has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; EsoCap AG; Janssen-Cilag AG; Lilly; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Speaker for AbbVie Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Co-Chair/PlannerJonathan Spergel, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ARS Pharmaceutical; DBV Technologies; Kaleo, Inc.; ReadySetFood; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/RGF865. CME/MOC/AAPA credit will be available until December 27, 2024.Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerPD Dr. med. Luc Biedermann has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; EsoCap AG; Janssen-Cilag AG; Lilly; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Speaker for AbbVie Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Co-Chair/PlannerJonathan Spergel, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ARS Pharmaceutical; DBV Technologies; Kaleo, Inc.; ReadySetFood; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/RGF865. CME/MOC/AAPA credit will be available until December 27, 2024.Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerPD Dr. med. Luc Biedermann has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; EsoCap AG; Janssen-Cilag AG; Lilly; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Speaker for AbbVie Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Co-Chair/PlannerJonathan Spergel, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ARS Pharmaceutical; DBV Technologies; Kaleo, Inc.; ReadySetFood; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/RGF865. CME/MOC/AAPA credit will be available until December 27, 2024.Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerPD Dr. med. Luc Biedermann has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; EsoCap AG; Janssen-Cilag AG; Lilly; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Speaker for AbbVie Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Co-Chair/PlannerJonathan Spergel, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ARS Pharmaceutical; DBV Technologies; Kaleo, Inc.; ReadySetFood; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Charles Ruban, CEO at Verdot. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Charles, covering: Crossing the border from supply chain to R&D, lessons learned from a technician turned business leader Creating the most extensive peanut allergy clinical trial in the world and opting for an IPO instead of a big pharma licensing deal How a call from a PE firm led to a spectacular exit Designing and creating downstream bioprocessing equipment in a Patagonia-inspired way - intelligent, sustainable, and functional - is critical for the future Why you need to know several biopharma trends, including AI, China R&D, and the fastest-growing therapeutic segment... you need to know Over the last 25 years, Charles has held rich and diverse executive leadership positions in fast-growing international healthcare companies. His experience includes Manufacturing, Research and development, Business development, and Global Management in biotechnology and biopharmaceutical companies. Charles is the CEO of VERDOT, a key player in bioprocessing, serving advanced solutions to the biotechnology and biopharmaceutical industry worldwide. Before this, he was the co-CEO at HTL Biotechnology, COO of DBV Technologies, and also spent considerable time at Eurogroup Consulting and Stallergenes. He has been instrumental in streamlining supply chain operations, establishing strategic alliances, developing and launching therapeutic biologics in Europe, the United States, and Japan, and performing business activities. He has been heavily exposed to investors in both public and private environments.   Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.  

This week, Jonathan is joined by Drew Bird, Director of the Food Allergy Center at Children's Health, Dallas, Texas, USA, to dive into environmental factors that have led to the increase in allergies, including peanut allergy, and oral immunotherapy as a treatment for allergies. The pair further discuss misconceptions and misinformation around allergies, and which allergies need more attention. Use the following timestamps to navigate the topics discussed in this episode: (00:00)-Introduction (02:28)-Bird's career in paediatric allergy and immunology (04:50)-Misconceptions in the field (08:47)-Using food proteins for immunotherapy (11:53)-Bird's role as Director of the Food Allergy Center at Children's Health (16:46)-Unmet needs in paediatric food allergies (18:05)-The PALISADE Study (19:39)-Food protein-induced enterocolitis syndrome (21:46)-Environmental factors and emerging allergies (26:36)-Innovations in the allergy and immunology field (30:51)-Advocating for young patients to promote effective healthcare (33:15)-Bird's three wishes for the future of healthcare   Prof Bird has the following disclosures: Consultant for AllerGenis, Allergy Therapeutics, Ltd, Before Brands, DBV Technologies, FARE, Genentech, HAL Allergy, Novartis, and Nutricia; and has received grant funding (institution) from Aimmune, Astellas, DBV Technologies, FARE, Genentech, NIH NIAID, Novartis, Regeneron and Siolta.

The UCP and NDP will face-off in the only ‘leader debate' of the campaign on Thursday night. What can we expect to see from the two party leaders and just how important is a debate in terms of an election outcome? We discuss with Former Conservative Cabinet Minister, The Honorable Monte Solberg. Peanuts are one of the most common allergens in the world. We hear details on new research from bio-pharmaceutical company “DBV Technologies” which is a treatment for Peanut Allergies presented as a simple as a ‘patch' which blocks the allergen properties of the popular nut. Finally, we catch up with Canadian Country Music Royalty! Terri Clark will be inducted into the Canadian Music Hall of Fame this week, and then she's hitting the road for a nationwide tour with Paul Brandt. We talk with the musical duo, who also happen to be longtime friends!

We're exploring the world of nutrition, food aversion, and challenges created by health conditions impacted by food. Meghan McNeill, MS, RD, LD, from Cincinnati Children's Center for Eosinophilic Disorders (CCED), is joining us today to share tips and ideas to tackle these challenges. To keep you in the know, here are a few helpful links:Solid Starts: Starting solids, baby-led weaning and information about first foods including texturesCincinnati Children's Center for Eosinophilic DisordersThe International Network for Diet and Nutrition in Allergy (INDANA)Academy of Nutrition and Dietetics You can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher, iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube. Contact us directly via Email.Sponsored by: DBV Technologies* Please note that today's guest was not sponsored by DBV Technologies or compensated in any way by the sponsor to participate in this specific podcast.

In this episode, we explore Back-to-School from the parent/caregiver perspective with FAACT's Vice President of Education, Kristin Osborne. Kristin shares some of her famous tips, such as using a musical play list to find inspiration for accommodation meetings!To keep you in the know, here are a few links to topics mentioned in the podcast:FAACT's Education Downloads (FREE downloads)FAACT's Anaphylaxis Signs and Symptoms Poster (FREE download)Kristin's Playlist - a few songs for inspiration:"Shake it off" - Taylor Swift"We are Family" - Sister SledgeFAACT's Planning for School - A Parent's GuideFAACT's Civil Rights Advocacy Resource Center - Section 504 ResourcesFAACT's Family Activities at Home: Roleplay for the Classroom ScenarioFAACT's Civil Rights Advocacy PodcastsContact Amelia Smith, JD, FAACT's Vice President of Civil Rights Advocacy, at Amelia.Smith@FoodAllergyAwareness.orgYou can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher, iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube.  Contact us directly via Email.Sponsored by: DBV Technologies

Dans ce numéro du journal des biotechs, Frédéric Gomez, analyste chez Pharmium Securities, livre ses réflexions sur les dossiers emblématiques de la cote biotech française et leur actualité récente : DBV Technologies et Valneva. Il en profite pour nous faire découvrir les qualités d'une biotech belge : Argenix. L'entretien est consacrée à Nawal Ouzren, directrice générale générale de Sensorion. Elle revient notamment sur l'approbation en France du lancement de l'essai clinique de « preuve de concept » de SENS-401 pour la préservation de l'audition résiduelle suite à une implantation cochléaire. Elle détaille l'avancée des programmes de thérapie génique en partenariat avec l'Institut Pasteur et évoque également le cours de Bourse de Sensorion.

C'est une deuxième séance consécutive dans le rouge pour la Bourse de Paris avec encore une fois un volume d'échanges très faible, sous les 3 milliards d'euros à la clôture. L'attentisme domine sur les marchés dans l'attente de la réunion de la BCE demain et des chiffres de l'inflation américaine vendredi. Le CAC 40 termine la séance sur un recul de 0,8% vers les 6448 points. Du côté des valeurs, L'automobile est à l'honneur. Renault grimpe de 3,79%, plus forte hausse de l'indice. Le groupe est en effet porté par son programme de rachat d'actions Stellantis en profite et avance de 0,56%. En hausse également, TotalEnergies qui grimpe de 1,45%. Le titre est sur ses plus hauts de 2018, tout comme les cours du pétrole qui reviennent eux aussi sur des plus hauts depuis début mars. De son côté, Safran gagne 0,39%, bénéficiant (un peu) d'un relèvement de recommandation d'Exane BNP Paribas qui passe à "superformance" contre "neutre" et révise son objectif de cours à 134 euros contre 120 euros. A contrario, l'inflation au plus haut pénalise les valeurs de la consommation. Danone chute de 2,72%. Pernod Ricard est également à la peine et lâche -2,5%. Sur le SBF 120, Soitec se distingue, le groupe publie ce soir ses résultats annuels. Autre ambiance du côté de Korian qui plonge après des informations du Parisien sur des plaintes de familles. Don son sillage, le gestionnaire de maisons de retraite Orpea se replie après une perquisition des locaux qui a eu lieu ce matin A noter aussi sur le SRD, ce décollage de DBV Technologies qui avance de 15 % à la faveur de résultats positifs d'une étude clinique sur le Viaskin Peanut, un traitement de l'allergie à l'arachide chez les enfants âgés de un à trois ans. Outre-Atlantique et sans surprise là aussi, la Bourse de New York a entamé la journée en ordre dispersé.

In this episode, we're talking about food allergen safe food! More than just a cookbook, The Everything Nut Allergy Cookbook, authored by FAACT's Director of Marketing, Lisa Horne, covers delicious recipes and how to substitute ingredients to customize meals to fit the allergen needs of your family. We explore how to use this cookbook as a learning tool to educate others about food allergies. Sharing personal stories, advice and tips as a fellow food allergy mom, Lisa's warm and friendly personality shines in this podcast as she shares highlights from The Everything Nut Allergy Cookbook.To keep you in the know, below are helpful links:Where to buy The Everything Nut Allergy Cookbook: Available wherever books are soldFood Allergy PI BlogFind Lisa Horne on social media at @foodallergypi (Twitter, Facebook and Instagram)Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube. Contact us directly via Email.You can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher, iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Sponsored by: DBV Technologies

This episode is Part 2 of a two-part series exploring strategies for powerhouse eating for teens and college students who are athletes or on the move. FAACT Medical Advisory Board member and registered dietician, Alison Cassin, MS, RD, LD, who works at Cincinnati Children's Center for Eosinophilic Disorders (CCED), provides nutritional information and pro tips. Get your notebook ready - you won't want to miss this information-packed episode as we take an even deeper dive into eating on the road and strategies to avoid cross-contact while staying hydrated.To keep you in the know, here are a few helpful links:FAACT's Allergen-Friendly Recipes on PinterestFAACT's Shopping, Cooking and Eating with Food Allergies FAACT's College Resource CenterThe International Network for Diet and Nutrition in Allergy (INDANA)Academy of Nutrition and Dietetics You can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher, iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube. Contact us directly via Email.Sponsored by: DBV Technologies* Please note that today's guest was not sponsored by DBV Technologies or compensated in any way by the sponsor to participate in this specific podcast.

This is Part 1 of a two-part series exploring strategies for a powerhouse diet for teens and college students who are active and on the move. FAACT Medical Advisory Board member and registered dietician, Alison Cassin, MS, RD, LD, who works at Cincinnati Children's Center for Eosinophilic Disorders (CCED), provides nutritional information and tips for active youth and athletes.To keep you in the know, here are a few helpful links:FAACT's Allergen-Friendly Recipes on PinterestShopping, Cooking and Eating with Food Allergies - FAACT's College Resource CenterThe International Network for Diet and Nutrition in Allergy (INDANA)Academy of Nutrition and Dietetics You can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher, iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube. Contact us directly via Email.Sponsored by: DBV Technologies* Please note that today's guest was not sponsored by DBV Technologies or compensated in any way by the sponsor to participate in this specific podcast.

In this episode, Kristin M. Osborne, FAACT's Vice President of Education, invites us into her home to discover heartfelt and exciting new ideas for safely celebrating Valentine's Day with food allergies. Everyone will find a fun new idea to enjoy Valentine's Day - from unique gift ideas to make-you-smile traditions and delicious treats.To keep you in the know, below are helpful links:Valentine's Day Crossword Puzzles and Word Searches Allergy-Friendly Valentine's Day Ideas on Pinterest FAACT's Allergy-Friendly Recipes on Pinterest Kahoot App - This app was mentioned in today's podcast as a fun school activity. Please note that FAACT does not endorse Kahoot and was not sponsored by Kahoot.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube. Contact us directly via Email.You can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher,  iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Sponsored by:  DBV Technologies

Dans ce premier numéro de l'année du Journal des biotechs, Frédéric Gomez, analyste chez Pharmium Securities, revient sur les grosses news tombées fin 2021 sur Genfit et DBV Technologies et nous explique ce qu'il faut attendre dans les mois qui viennent.

Dans ce premier numéro de l'année du Journal des biotechs, Frédéric Gomez, analyste chez Pharmium Securities, revient sur les grosses news tombées fin 2021 sur Genfit et DBV Technologies et nous explique ce qu'il faut attendre dans les mois qui viennent. L'entretien est consacré à Didier Laurens. Le directeur général d'Advicenne livre des précisions sur le newsflow positif très fourni de la biotech, entre signatures de partenariats ciblés, accord de remboursement en France et projets pour 2022.

Floods, fires, and hurricanes dominated the news of summer 2021. But those with food allergies need to remain prepared for natural disasters and emergencies since access to safe foods may be challenging. We sit down with Kristin M. Osborne, FAACT's Vice President of Education, to explore how to create your own custom bag to grab-and-go if you need to leave your home quickly or if you need to shelter in place.To keep you in the know, below are helpful links:Center for Disease Control and Prevention's Family Emergency Kit Checklist FAACT's College Resource CenterYou can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher,  iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Follow us on Facebook, Twitter, Instagram, LinkedIn, & Pinterest.Sponsored by: DBV Technologies

In this episode, we sit down with board-certified allergist and pediatrician Zachary Rubin to explore how to vet news stories and information on the internet about food allergy and Covid-19. Dr. Rubin appears regularly on local TV and media in the Chicago area and uses Tik Tok and Twitter to help bust myths and lead followers to medically vetted scientific information  - sometimes while using a hula-hoop! To keep you in the know, here are a few links to topics mentioned in the podcast:Dr. Zachary Rubin on Twitter@rubin_allergy on Tik TokAmerican Academy of Allergy, Asthma and Immunology (AAAAI) American College of Allergy, Asthma and Immunology (ACAAI) Centers for Disease Control  and Prevention (CDC) - Covid-19 informationWorld Health Organization (WHO) You can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher,  iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube. Contact us directly via Email.Sponsored by:  DBV Technologies* Please note that today's guest was not sponsored by DBV Technologies or compensated in any way by the sponsor to participate in this specific podcast.

This episode takes a deep dive into the nutrition challenges faced by families managing EoE and food allergies. FAACT Medical Advisory Board member Alison Cassin, MS, RD, LD, who works at Cincinnati Children's Center for Eosinophilic Disorders (CCED), provides nutritional tips for active children and athletes. To keep you in the know, here are a few helpful links:FAACT's Allergen-Friendly Recipes on PinterestFAACT's Find a Support Group Near YouThe International Network for Diet and Nutrition in Allergy (INDANA)Academy of Nutrition and Dietetics You can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher,  iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube. Contact us directly via Email.Sponsored by: DBV Technologies* Please note that today's guest was not sponsored by DBV Technologies or compensated in any way by the sponsor to participate in this specific podcast.

Heading Back-to-School with food allergies can be challenging, but anxiety might be higher this year as the Covid-19 Pandemic continues. We're sitting down with FAACT's Director of Behavioral Health, Emery Brown, MA, Ed.S., NCSP, School Psychology, to discover tools to help families keep anxiety in check and how to create a positive environment surrounding school. Ms. Brown provides fresh and positive questions parents can ask to help start engaging conversations and tips on how to keep self-care in the background.To keep you in the know, here are helpful resources:Podcasts:Back to School Fall 2021 Readiness: Understanding 504's  and Accommodations with Amelia Smith, JDYour Family: Building Resilience in KidsFood Allergy Anxiety and DepressionSelf-care and Coping Skills: Tips for You and Your FamilyBlogs:The Lost Memories of Students in Transition: Where Do We Go from Here?Compassion in a Time of Chaos: There is No Right ResponseResources:FAACT's 'My Food Allergy Resilience Kit'FAACT's 'Parents: How to Listen to Your Children and Teens When They Are Ready to Talk to You About Their Mental Health'FAACT's 'When It's Time to Seek Help: Behavioral Health Issues and Your Food Allergies'FAACT's Self-care SectionYou can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher,  iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Follow us on Facebook, Twitter, Instagram, LinkedIn, & Pinterest.Sponsored by: DBV Technologies

In this special extended-length edition Back to School podcast, we explore recovery and how to create a solid return to school in the fall, even if your student was able to partially attend school last spring. We discuss all academic phases, including challenges and tips: elementary, middle, and high school plus college.To help parents and caregivers prepare for the transition, we're sitting down with FAACT's Director of Behavioral Health, Emery Brown, MA, Ed.S., NCSP, School Psychology, to discover tools to mentally prepare your student and your family for this unusual and much-welcomed return to the classroom.To keep you in the know, here are helpful resources:Podcasts:Your Family: Building Resilience in KidsFood Allergy Anxiety and DepressionSelf-care and Coping Skills: Tips for You and Your FamilyBlogs:The Lost Memories of Students in Transition: Where Do We Go from Here?Compassion in a Time of Chaos: There is No Right ResponseResources:FAACT's 'My Food Allergy Resilience Kit'FAACT's 'Parents: How to Listen to Your Children and Teens When They Are Ready to Talk to You About Their Mental Health'FAACT's 'When It's Time to Seek Help: Behavioral Health Issues and Your Food Allergies'FAACT's Self-care SectionYou can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher,  iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Follow us on Facebook, Twitter, Instagram, LinkedIn, & Pinterest.Sponsored by: DBV Technologies

In this episode of Meeting Mic, we bring you pearls and perspectives from the American Thoracic Society 2021 International Conference, as well as Healio's top headlines from the virtual meeting. Leonard Bacharier, MD, discusses results of the VOYAGE study of dupilumab in children with asthma :35 Dennis Hwang, MD, shares data from a study that looked at severe obstructive sleep apnea and COVID-19 risk 7:11 Alayna Tackett, PhD, discusses results of her analysis of e-cigarette use and the association with wheeze and shortness of breath, even in young adults who don't smoke 10:25 Michael Wechsler, MD, shares data from the LIBERTY ASTHMA TRAVERSE Extension Study, which assessed long-term maintenance of oral corticosteroid reduction and efficacy with dupilumab in patients with asthma 14:01 Ana Hernandez Cordero, PhD, discusses data from an integrative genomic analysis of potential genetic risk factors for COVID-19 23:15 Read the full coverage here: https://www.healio.com/news/pulmonology/20210519/tezepelumab-reduces-exacerbations-in-broad-population-of-patients-with-severe-asthma https://www.healio.com/news/pulmonology/20210518/multiple-disease-progression-events-less-likely-with-continued-inhaled-treprostinil https://www.healio.com/news/pulmonology/20210517/monoclonal-antibody-cocktail-cut-covid19-hospitalization-death-by-70-in-outpatient-setting https://www.healio.com/news/pulmonology/20210516/fauci-covid19-vaccines-the-bright-light-of-this-extraordinary-challenge Disclosures: Bacharier reports he received speaker fees from AstraZeneca, GlaxoSmithKline, Regeneron and Sanofi; was on the data safety monitoring board for Cystic Fibrosis Foundation and DBV Technologies; and received research support from NIH, Sanofi and Vectura. Hernandez Cortez reports funding from MITACS and Providence Health Center. Hwang reports that efforts for the study were supported by grants from the American Academy of Sleep Medicine Foundation and from internal Kaiser research support. Tackett reports no relevant financial disclosures. The research was supported by the National Heart Lung and Blood Institute from the NIH and the Oklahoma Tobacco Settlement Endowment Trust. Wechsler reports he received consultant fees from AstraZeneca, Amgen, Boehringer Ingelheim, Cohero Health, Equillium, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi, Sentien and Teva.

In this episode, FAACT's General Counsel and Vice President of Civil Rights Advocacy, Amelia G. Smith, JD, explores the recently released international food allergy guidelines and how they apply to you and your family. Ms. Smith explains using easy-to-understand terms, elements of the recommendations, and how you can keep the focus on your student's health needs.To keep you in the know, here are some helpful links:Special Note: Please contact Amelia.Smith@FoodAllergyAwareness.org directly if you are experiencing challenges regarding 504 accommodations or receiving meals, which are no longer safe and appropriate for your student. Back to School 2021: 504 Basics and Accommodations as Students Return to School - FAACT Podcast with Amelia SmithFAACT's Civil Rights Advocacy Resource CenterAASA The School Superintendents Association: FAACT's Guest Blog on COVID-19 and Students with Food AllergiesFAACT's Podcast Ep. 26: COVID-19 Back-To-School Must KnowsFAACT's Podcast Ep. 12: Civil Rights Advocacy - Responding to the CDC's Interim Guidance and Meals in the ClassroomFAACT's Position Statement and Letter to the CDC regarding CDC's Interim Guidance and Meals in the ClassroomYou can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher, iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, & YouTube.Sponsored by: DBV Technologies

Dans ce numéro du journal des biotechs, Frédéric Gomez, analyste chez Pharmium Securities fait un focus sur trois dossiers : DBV Technologies, Inventiva, Median Technologies L'entretien est consacré à Pascal Prigent, directeur général de Genfit. Il détaille notamment la stratégie du groupe dans de nouvelles indications avec le lancement d'essais cliniques d'ici la fin de l'année.

Mercialys, Eramet, Valneva, DBV Technologies : 4 actions dont le cours explose depuis le 1er janvier. Les explications de Laurent Grassin, directeur de la rédaction Boursorama. Ecorama du 6 mai 2021, présenté par David Jacquot sur Boursorama.com

La Bourse de Paris se reprend après la séance d'hier. Les bons résultats d'entreprises et de solides indicateurs permettent au CAC 40 de s'offrir une progression de 1,40% vers les 6339 points. Du côté des valeurs, L'automobile est recherché avec Stellantis qui s'offre une hausse de plus de 7%, après la publication de ses résultats qui révèlent une croissance de son chiffre d'affaires au premier trimestre dans le haut de la fourchette des prévisions du marché, et ce malgré la pénurie de puces. Le groupe dit par ailleurs s'attendre à une bonne performance commerciale et financière au deuxième trimestre. Les valeurs cycliques sensibles à la conjoncture économique et qui devraient profiter de la reprise économique et des différents plans de relance sont très bien orientées avec Saint-Gobain, presque 5% de hausse. Le titre bénéficie également d'un relèvement d'objectif de cours de 46 à 55 euros par Independent Research. ArcelorMittal +4,76% est de son côté dopé par la hausse des cours du minerai de fer. Total +3,58% grimpe dans le sillage de la hausse des cours du pétrole. A l'inverse, le marché semble ne pas être convaincu par les résultats de Veolia. Le titre lâche 1%. La foncière commerciale Unibail-Rodamco-Westfield recule de 0,47%. Alstom s'est finalement repris en fin de séance. Bombardier a annoncé la vente de sa participation de 3,1% dans le groupe français. Sur le SBF 120, JC Decaux est propulsé en tête, les investisseurs favorisent là aussi les valeurs qui devraient profiter du fort rebond de l'économie. Eramet est également à la hausse. Le groupe serait proche d'un accord, selon Reuters pour la vente du fournisseur de l'industrie aéronautique Brown Europe au fonds d'investissement ACE Capital Partners dans le cadre de sa stratégie de recentrage sur ses activités minières. A contrario, Valneva chute près avoir dévoilé la fourchette de prix indicative pour son projet d'introduction en Bourse au Nasdaq. DBV Technologies est toujours à la peine pénalisé par le coût du plan de restructuration en cours. Outre-Atlantique, la Bourse de New York repart à la hausse portée par le léger rebond des grandes valeurs technologiques et de solides données sur l'emploi dans le privé. L'enquête mensuelle ADP révèle que 742.000 emplois ont été créé le mois dernier contre 565.000 en mars. Voilà c'est tout pour ce soir mais n'oubliez pas toute l'actualité économique et financière est sur Boursorama.

This is Part 2 of a two-part series exploring when it is time to consume allergens from the perspectives of board-certified allergists. Listen and learn today with FAACT.We conclude this information-packed series with two allergists: Brian Schroer, MD, Division Director of Allergy and Immunology at Akron Children's Hospital and Associate Professor Pediatrics Northeast Ohio College of Medicine and Douglas P. Mack, MSc, MD, FRCPC, FCSACI Board of Directors - Canadian Society of Allergy and Clinical Immunology, Pediatric Allergy, Asthma and Immunology, and Assistant Clinical Professor, McMaster University.To keep you in the know, here are a few links to topics mentioned in the podcast:Eating Baked, Roasted or Raw - Food Allergen Must-Knows (Part 1 - the Registered Dietician Perspective) - FAACT Roundtable Podcast Ep. 62"Practical Challenges and Considerations for Early Introduction of Potential Food Allergens for Prevention of Food Allergy" Research Paper You can find FAACT's Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher, iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube. Contact us directly via Email.Sponsored by:  DBV Technologies*Please note that today's guests were not sponsored by DBV Technologies or compensated in any way by the sponsor to participate in this specific podcast.

This is Part 1 of a two-part series exploring when it is time to consume allergens from the perspectives of registered dieticians and board-certified allergists. Have you heard of the egg or milk ladder? Do you know the difference between the amount of milk allergen baked in a muffin versus a cup of milk? Listen and learn today with FAACT!We kick off this fascinating series with two experts in the area of diet and food allergies - Marion Groetch, MS, RDN, Director of Nutrition Services at the Elliot and Roslyn Jaffe Food Allergy Institute, and Assistant Professor of Pediatrics Division of Allergy & Immunology at the Icahn School of Medicine at Mount Sinai and Carina Venter Ph.D., RD, Associate Professor of Pediatrics, Section of Allergy & Immunology at the University of Colorado Denver School of Medicine, Children's Hospital Colorado.To keep you in the know, here are a few links to topics mentioned in the podcast:INDANA - The International Network for Diet and Nutrition in AllergyMilk Ladder* NOTE: always speak to your doctor before changing your diet or that of someone you care for.Egg Ladder * NOTE: always speak to your doctor before changing your diet or that of someone you care for."Practical Challenges and Considerations for Early Introduction of Potential Food Allergens for Prevention of Food Allergy" Research Paper You can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher,  iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube. Contact us directly via Email.Sponsored by:  DBV Technologies Please note that today's guests were not sponsored by DBV Technologies or compensated in any way by the sponsor to participate in this specific podcast.

In this episode, we sit down with Gwen Smith, Editor and Content Chief of Allergic Living, to take a peek behind the scenes of America's favorite food allergy and asthma news source. Ms. Smith shares personal stories of her first reaction as an adult and what inspired Allergic Living. We explore memorable stories and why educating the public is at the heart of Ms. Smith's passion. To keep you in the know, here are links mentioned in the podcast:Allergic Living'This Allergic Life' Microsite Contact Gwen Smith at: editor@allergicliving.com You can find the FAACT Roundtable Podcast on Apple Podcast, Spotify, Google Podcast, Stitcher,  iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube. Contact us directly via Email.Sponsored by: DBV Technologies

In this episode, we explore Post Traumatic Stress Disorder (PTSD), how to identify it, and what to do if you suspect a loved one might be experiencing PTSD. As we speak with FAACT's Director of Behavioral Health, Emery Brown, MA, School Psychology, we'll learn about medical PTSD, although rare, and post-traumatic growth, as well!Links and resources mentioned in today's podcast:Podcasts:Your Family: Building Resilience in KidsFood Allergy Anxiety and DepressionSelf-care and Coping Skills Tips for You and Your FamilyBlogs:Mental Health Awareness Month: The Effects of PTSD and Food AllergiesThe Lost Memories of Students in Transition: Where Do We Go from Here?Compassion in a Time of Chaos: There is No Right ResponseResources:FAACT's 'My Food Allergy Resilience Kit'FAACT's 'Parents: How to Listen to Your Children and Teens When They Are Ready to Talk to You About Their Mental Health'FAACT's 'When It's Time to Seek Help: Behavioral Health Issues and Your Food Allergies'FAACT's Self-care SectionYou can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher,  iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Follow us on Facebook, Twitter, Instagram, LinkedIn, & Pinterest.Sponsored by: DBV Technologies

Pandemic parenting has been a challenge! Today, we sit down with FAACT's Director of Behavioral Health, Emery Gewirtz, MA, School Psychology,  as we explore what emotions kids might be feeling right now and how to help establish fun winter goals, routines, and tips to perk up the pandemic winter blues. Listen to Emery's top three tips for engagement, including how to help your child remain engaged with their peers and friends.Links mentioned in podcast:Cosmic Kids Yoga - YouTube Yoga Club for KidsFAACT's Behavioral Health Resource CenterPodcasts:Your Family: Building Resilience in KidsFood Allergy Anxiety and DepressionSelf-Care and Coping Skills Tips for Your and Your FamilyBlogs:Mental Health Awareness Month: The Effects of PTSD and Food AllergiesThe Lost Memories of Students in Transition: Where Do We Go from Here?Compassion in a Time of Chaos: There is No Right ResponseResources:FAACT's Parents: How to Listen to Your Children and Teens When They Are Ready to Talk to You About Their Mental HealthFAACT's When It's Time to Seek Help: Behavioral Health Issues and Your Food AllergiesYou can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher,  iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Follow us on Facebook, Twitter, Instagram, LinkedIn, & Pinterest.Sponsored by: DBV Technologies

This holiday season, we explore how to set a positive intention, learn how to say "No" with grace and honesty, and how to "take in the good" with Emery Gewirtz, FAACT Director of Behavioral Health. The holidays can be tough, but with tools packed with science-based tips, you'll be prepared for a joyful season.To keep you in the know, below are a few, free & helpful links:Holiday Helpers:FAACT's “What Will Your Holiday Season Look Like?” BlogFAACT's Holiday Planning Section FAACT's Self-care SectionFAACT's Behavioral Health Resource CenterPodcasts:Your Family: Building Resilience in KidsFood Allergy Anxiety and DepressionSelf-Care and Coping Skills Tips for Your and Your FamilyBlogs:Mental Health Awareness Month: The Effects of PTSD and Food AllergiesThe Lost Memories of Students in Transition: Where Do We Go from Here?Compassion in a Time of Chaos: There is No Right ResponseResources:FAACT's Parents: How to Listen to Your Children and Teens When They Are Ready to Talk to You About Their Mental HealthFAACT's When It's Time to Seek Help: Behavioral Health Issues and Your Food AllergiesYou can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher,  iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Follow us on Facebook, Twitter, Instagram, LinkedIn, & Pinterest.Sponsored by: DBV Technologies

In this episode, we explore the science behind how food manufacturers detect allergens with Melanie Downs, PhD, Associate Professor at the University of Nebraska-Lincoln, Department of Food Science and Technology. Learn about spectrometry and how testing food samples sometimes uses the same technology used in COVID-19 rapid testing. Dr. Downs explains what type of research is conducted at the Food Allergy Research & Resource Program (FARRP) and how it impacts people managing food allergies.To keep you in the know, below is a helpful link:Food Allergy Research & Resource Program (FARRP): University of Nebraska, LincolnMelanie Downs, PhD BioYou can find FAACT's Roundtable Podcast on Apple Podcast, Spotify, Google Podcast, Stitcher,  iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube. Contact us directly via Email.Sponsored by: DBV Technologies

Thomas Silvera tragically lost his son, Elijah, to a food allergic reaction. Now, Thomas and his family are changing the lives of thousands of children with food allergies globally. We sit down with Thomas to learn about his family's latest endeavors and newest announcements.To keep you in the know, below are a few, free and helpful links to our downloadable materials:Elijah-Alavi FoundationElijah's Echo Ambassador ProgramBelay Food Allergy Training and Preparedness Program - Partnership with Elijah-Alavi FoundationYou can find the FAACT Roundtable Podcast on Apple Podcast, Spotify, Google Podcast, Stitcher,  iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube. Contact us directly via Email.Sponsored by: DBV Technologies